farnesol has been researched along with Cirrhoses, Experimental Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aeed, H; Bruck, R; Kloog, Y; Kweon, YO; Reich, R; Reif, S; Shilo, Y | 1 |
| Aeed, H; Avni, Y; Bruck, R; Gana-Weis, M; Kloog, Y; Pinzani, M; Reif, S; Romanelli, RG; Weis, B; Zaidel, L | 1 |
2 other study(ies) available for farnesol and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Topics: Animals; Apoptosis; Farnesol; Gene Expression; Genes, ras; Hydroxyproline; In Situ Nick-End Labeling; Liver; Liver Cirrhosis, Experimental; Male; Metalloproteases; Organ Size; Rats; Rats, Wistar; Salicylates; Spleen; Thioacetamide; Tissue Inhibitor of Metalloproteinase-2 | 2004 |
The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Farnesol; Humans; Liver Cirrhosis, Experimental; Male; ras Proteins; Rats; Rats, Wistar; Salicylates | 1999 |